Literature DB >> 16115052

CD56 staining in Merkel cell carcinoma and natural killer-cell lymphoma: magic bullet, diagnostic pitfall, or both?

Jennifer M McNiff1, Shawn E Cowper, Rossitza Lazova, Antonio Subtil, Earl J Glusac.   

Abstract

BACKGROUND: Antibodies to CD56 label natural killer (NK) cell lymphomas and neuroendocrine tumors such as Merkel cell carcinoma (MCC). In MCC altered by crush artifact or obscured by lymphocytes, the histologic features coupled with CD56 positivity can lead to an erroneous impression of NK-cell lymphoma.
METHODS: Eighteen cases of MCC were stained for CD56, CK20, MNF116, and pankeratin. The results were compared to histologic features and CD56 staining pattern of three NK-cell lymphomas.
RESULTS: Three of 18 cases of MCC histologically resembled lymphoma, and CD56 positivity with CD3 and CD20 negativity initially raised the possibility of NK-cell lymphoma. Two additional cases were obscured by dense inflammation, again suggesting the diagnosis of lymphoma. Seventeen of 18 MCC labeled for CD56 and an equal number stained for CK20. All MCC tested were positive for CAM5.2 (14/14) and MNF116 (17/17). Antibodies to pankeratin labeled only one of 18 MCC. Staining for CD56 was stronger in MCC than NK-cell lymphomas.
CONCLUSIONS: CD56 is a sensitive marker for MCC as well as for NK-cell lymphoma, but is not specific. Importantly, CD56 positivity in crushed or inflamed biopsies of MCC may lead to an erroneous impression of NK lymphoma. Awareness of this potential pitfall will prevent misdiagnosis. McNiff JM, Cowper SE, Lazova R, Subtil A, Glusac EJ. CD56 staining in Merkel cell carcinoma and natural killer-cell lymphoma: Magic bullet, diagnostic pitfall, or both?

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115052     DOI: 10.1111/j.0303-6987.2005.00378.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  9 in total

Review 1.  Merkel cell carcinoma: what do we know about it and what should we do?

Authors:  Isabel Prieto Muñoz; José Pardo Masferrer; Jesús Olivera Vegas; José Ramón Fortes Alen; Ana M Pérez Casas
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

Review 2.  [Merkel cell carcinoma: cutaneous manifestation of a highly malignant pre-/pro-B cell neoplasia? : Novel concept about the cellular origin of Merkel cell carcinoma].

Authors:  C M Sauer; E Chteinberg; D Rennspiess; A K Kurz; A Zur Hausen
Journal:  Hautarzt       Date:  2017-03       Impact factor: 0.751

3.  [Merkel cell carcinoma].

Authors:  F Kleffner; J Schürholz; S Burckhardt; C Mauch; M Schlaak
Journal:  Hautarzt       Date:  2014-09       Impact factor: 0.751

4.  Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.

Authors:  Kelly G Paulson; Jayasri G Iyer; Andrew R Tegeder; Renee Thibodeau; Janell Schelter; Shinichi Koba; David Schrama; William T Simonson; Bianca D Lemos; David R Byrd; David M Koelle; Denise A Galloway; J Helen Leonard; Margaret M Madeleine; Zsolt B Argenyi; Mary L Disis; Juergen C Becker; Michele A Cleary; Paul Nghiem
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

5.  Merkel cells as putative regulatory cells in skin disorders: an in vitro study.

Authors:  Nicholas Boulais; Ulysse Pereira; Nicolas Lebonvallet; Eric Gobin; Germaine Dorange; Nathalie Rougier; Christophe Chesne; Laurent Misery
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

6.  An unusual case of Merkel cell carcinoma.

Authors:  Eva-Susanne Strobel; Petra Feyer; Maria Steingräber; Annette Schmitt-Gräff; Peter Karl Kohl
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-25       Impact factor: 4.553

7.  Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.

Authors:  Manisha H Shah; Paul Lorigan; Mary E R O'Brien; Frank V Fossella; Kathleen N Moore; Shailender Bhatia; Maurice Kirby; Penella J Woll
Journal:  Invest New Drugs       Date:  2016-03-09       Impact factor: 3.850

8.  Evaluating blood levels of neuron specific enolase, chromogranin A, and circulating tumor cells as Merkel cell carcinoma biomarkers.

Authors:  Maria Rita Gaiser; Kenneth Daily; Jochen Hoffmann; Maik Brune; Alexander Enk; Isaac Brownell
Journal:  Oncotarget       Date:  2015-09-22

9.  Merkel cell carcinoma.

Authors:  Virve Koljonen
Journal:  World J Surg Oncol       Date:  2006-02-08       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.